Literature DB >> 3034177

Marked hyperbilirubinemia in infectious mononucleosis. Analysis of laboratory data in seven patients.

S A Fuhrman, R Gill, C A Horwitz, W Henle, G Henle, G Kravitz, J Baldwin, J Tombers.   

Abstract

While mild to moderate hepatic dysfunction is commonly encountered in infectious mononucleosis induced by Epstein-Barr virus (EBV), clinical jaundice with high bilirubin levels (greater than or equal to 6.0 mg/dL [greater than or equal to 103 mumol/L] is only occasionally encountered. In this study, seven patients with primary EBV infections had peak bilirubin levels of 10.2 to 23.0 mg/dL (174 to 393 mumol/L) and, for the most part, presented initial diagnostic problems. Complications included the virus-associated hemophagocytic syndrome and acute respiratory distress syndrome in one patient and transient renal failure in another. The laboratory data suggested that a combination of hemolysis and viral-induced cholestasis was responsible for the intense hyperbilirubinemia in at least five patients. Physicians should be aware that marked hyperbilirubinemia can occur with EBV-induced infectious mononucleosis and, thereby, obviate the need for costly diagnostic laboratory tests and, occasionally, invasive procedures.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034177

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

1.  Intense pruritus in Epstein-Barr virus (EBV) hepatitis treated with naloxone drip.

Authors:  Satyanisth Agrawal; Ryan O'Connor; Elie Aoun; Michael Babich
Journal:  BMJ Case Rep       Date:  2015-01-27

2.  Intrahepatic cholestasis as a paraneoplastic syndrome associated with pheochromocytoma.

Authors:  C H Chung; C H Wang; C Y Tzen; C P Liu
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

3.  Correlates of illness severity in infectious mononucleosis.

Authors:  John Odame; Joan Robinson; Nasser Khodai-Booran; Simon Yeung; Tony Mazzulli; Derek Stephens; Upton D Allen
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-09       Impact factor: 2.471

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.